



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# UT961 : Endometrium cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores

Microarray Panel	Endometrial endometrioid adenocarcinoma tissue microarray, containing 32 cases of endometrium endometrioid adenocarcinoma, 1 each of endometrium adenosquamous carcinoma, carcinosarcoma, stromal sarcoma, malignant mixed Mullerian Tumor and polyp, 2 each of endometrium adenomyosis and simple hyperplasia, 4 proliferative endometrium, plus 3 normal endometrium tissue, duplicate cores per case (duplicated cores from the same patient were put onto upper and lower rows in the same position)	
Cores	96	
Cases	48	
Row number	8	
Column number	12	
Core Diameter (mm)	1.5	
Thickness (µm)	5	
QA/QC	Anti-Actin confirmed	
Tissue Array Type	FFPE	
Species	Human	

**Applications** Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page.

**Notes**  
 1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). **To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C.** before putting into xylene for deparaffinization. Baked slides were sent out baked for 2 hours.  
 In the following specsheet, “\*” means invalid core; “-” means no applicable or negative in IHC markers.



**Legend:** Ute - Uterus  
 ● - Hyperplasia, ● - Malignant tumor, ● - Malignant tumor (stage IB), ● - Malignant tumor (stage III), ● - Malignant tumor (stage IIIa), ● - Malignant tumor (stage IIIc), ● - Malignant tumor (stage IIa), ● - Malignant tumor (stage Ia), ● - Malignant tumor (stage Ib), ● - Malignant tumor (stage Ic), ● - Normal tissue, ● - Polyp

, tissue IDs are available in exported Excel files.

Pos.	No.	Age	Sex	Organ/Anatomic Site	Pathology diagnosis	TNM	Grade	Stage	Type	Image
A1	1	60	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
A2	2	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	
A3	3	42	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	2	Ia	malignant	
A4	4	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant	
A5	5	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant	

A6	6	58	F	Uterus	Endometrioid adenocarcinoma (sparse)	T1aN0M0	1	Ia	malignant
A7	7	65	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant
A8	8	64	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant
A9	9	63	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
A10	10	63	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	2	IIIa	malignant
A11	11	46	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
A12	12	62	F	Uterus	Endometrioid adenocarcinoma	T1cN1M0	2	IIIc	malignant
B1	13	60	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
B2	14	51	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
B3	15	42	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	2	Ia	malignant
B4	16	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
B5	17	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
B6	18	58	F	Uterus	Endometrioid adenocarcinoma	T1aN0M0	1	Ia	malignant
B7	19	65	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant
B8	20	64	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	1	Ic	malignant
B9	21	63	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
B10	22	63	F	Uterus	Endometrioid adenocarcinoma	T3aN0M0	2	IIIa	malignant
B11	23	46	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
B12	24	62	F	Uterus	Endometrioid adenocarcinoma	T1cN1M0	2	IIIc	malignant
C1	25	58	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
C2	26	67	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
C3	27	56	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
C4	28	72	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
C5	29	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
C6	30	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
C7	31	54	F	Uterus	Adenocarcinoma (sparse)	T1bN0M0	2	Ib	malignant
C8	32	57	F	Uterus	Adenocarcinoma (sparse)	T1bN0M0	2	Ib	malignant
C9	33	49	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant
C10	34	60	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
C11	35	67	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant
C12	36	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
D1	37	58	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
D2	38	67	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
D3	39	56	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
D4	40	72	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
D5	41	62	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
D6	42	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	2	Ic	malignant
D7	43	54	F	Uterus	Endometrioid adenocarcinoma (smooth muscle)	T1bN0M0	-	Ib	malignant
D8	44	57	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	3	Ib	malignant
D9	45	49	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant
D10	46	60	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
D11	47	67	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	1	Ib	malignant
D12	48	50	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2	Ib	malignant
E1	49	56	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2--3	Ib	malignant
E2	50	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
E3	51	68	F	Uterus	Endometrioid adenocarcinoma with necrosis (sparse)	T1bN0M0	3	Ib	malignant
E4	52	48	F	Uterus	Endometrioid adenocarcinoma with necrosis	T3N0M0	3	III	malignant
E5	53	74	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
E6	54	44	F	Uterus	Endometrioid adenocarcinoma with necrosis (sparse)	T1bN0M0	3	Ib	malignant
E7	55	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
E8	56	35	F	Uterus	Endometrioid adenocarcinoma	T3N0M0	3	IIIa	malignant
E9	57	67	F	Uterus	Adenosquamous carcinoma	T2aN0M0	-	IIa	malignant
E10	58	54	F	Uterus	Carcinosarcoma	T1bN0M0	-	Ib	malignant
E11	59	26	F	Uterus	Low grade endometrial stromal sarcoma	T2N0M0 G1	-	IB	malignant

E12	60	60	F	Uterus	Malignant mixed Mullerian Tumor	T2N0M0 G1	-	IB	malignant
F1	61	56	F	Uterus	Endometrioid adenocarcinoma	T1bN0M0	2--3	Ib	malignant
F2	62	55	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
F3	63	68	F	Uterus	Endometrioid adenocarcinoma with necrosis (sparse)	T1bN0M0	3	Ib	malignant
F4	64	48	F	Uterus	Endometrioid adenocarcinoma with necrosis	T3N0M0	3	III	malignant
F5	65	74	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
F6	66	44	F	Uterus	Endometrioid adenocarcinoma with necrosis (sparse)	T1bN0M0	3	Ib	malignant
F7	67	58	F	Uterus	Endometrioid adenocarcinoma	T1cN0M0	3	Ic	malignant
F8	68	35	F	Uterus	Endometrioid adenocarcinoma	T3N0M0	3	IIIa	malignant
F9	69	67	F	Uterus	Adenosquamous carcinoma	T2aN0M0	-	IIa	malignant
F10	70	54	F	Uterus	Carcinosarcoma	T1bN0M0	-	Ib	malignant
F11	71	26	F	Uterus	Low grade endometrial stromal sarcoma	T2N0M0 G1	-	IB	malignant
F12	72	60	F	Uterus	Malignant mixed Mullerian Tumor	T2N0M0 G1	-	IB	malignant
G1	73	37	F	Uterus	Endometrial polyp	-	-	-	polyp
G2	74	52	F	Uterus	Adenomyosis	-	-	-	normal
G3	75	49	F	Uterus	Adenomyosis	-	-	-	normal
G4	76	49	F	Uterus	Endometrioid simple hyperplasia	-	-	-	hyperplasia
G5	77	57	F	Uterus	Endometrioid simple hyperplasia	-	-	-	hyperplasia
G6	78	58	F	Uterus	Proliferative endometrium	-	-	-	normal
G7	79	42	F	Uterus	Proliferative endometrium	-	-	-	normal
G8	80	32	F	Uterus	Proliferative endometrium	-	-	-	normal
G9	81	57	F	Uterus	Proliferative endometrium	-	-	-	normal
G10	82	18	F	Uterus	Normal endometrium tissue	-	-	-	normal
G11	83	21	F	Uterus	Normal endometrium tissue	-	-	-	normal
G12	84	21	F	Uterus	Normal endometrium tissue	-	-	-	normal
H1	85	37	F	Uterus	Endometrial polyp	-	-	-	polyp
H2	86	52	F	Uterus	Adenomyosis	-	-	-	normal
H3	87	49	F	Uterus	Adenomyosis	-	-	-	normal
H4	88	49	F	Uterus	Endometrioid simple hyperplasia	-	-	-	hyperplasia
H5	89	57	F	Uterus	Endometrioid simple hyperplasia	-	-	-	hyperplasia
H6	90	58	F	Uterus	Proliferative endometrium	-	-	-	normal
H7	91	42	F	Uterus	Proliferative endometrium	-	-	-	normal
H8	92	32	F	Uterus	Proliferative endometrium	-	-	-	normal
H9	93	57	F	Uterus	Proliferative endometrium	-	-	-	normal
H10	94	18	F	Uterus	Normal endometrium tissue	-	-	-	normal
H11	95	21	F	Uterus	Normal endometrium tissue	-	-	-	normal
H12	96	21	F	Uterus	Normal endometrium tissue	-	-	-	normal
-	0	42	M	Adrenal gland	Pheochromocytoma (tissue marker)	-	-	-	Malignant

## TNM grading:

### T - Primary tumor

Tx - Primary tumor cannot be assessed

T0 - No evidence of primary tumor

Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria

T1 - Tumor invades submucosa

T2 - Tumor invades muscularis propria

T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.

T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

### N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed

N0 - No regional lymph node metastasis

N1 - Metastasis in 1 to 3 regional lymph nodes

N2 - Metastasis in 4 or more regional lymph nodes

### M - Distant metastasis

Mx - Distant metastasis cannot be assessed

M0 - No distant metastasis

M1 - Distant metastasis

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)



**UK & Rest of the World**

184 Park Drive, Milton Park  
Abingdon OX14 4SE, U.K.  
T: +44 (0) 1235 828 200  
F: +44 (0) 1235 820 482



**North America**

1035 Cambridge Street,  
Cambridge, MA 02141.  
T: +1 (617) 945-5033 or  
T: +1 (800) 987-0985  
F: +1 (617) 945-8218



**Germany**

Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main  
T: +49 (0) 69 779099  
F: +49 (0) 69 13376880



**Switzerland**

Via Lisano 3  
(CP.683)  
6900 Massagno  
T: +41 (0) 91 604 55 22  
F: +41 (0) 91 605 17 85